A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects

Exclusion criteria

• . Blood donation or recipient of blood transfusion in previous 12 weeks.
• . History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatobiliary, immunological, renal, respiratory, or genitourinary abnormalities or diseases.
• . History of neoplastic disease (with the exception of adequately treated nonmelanomatous skin carcinoma).
• . Mentally or legally incapacitated (e.g. has significant emotional problems at the time of Screening Visit or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years).
• . Fever (body temperature \>38 C) or symptomatic viral/bacterial infection or use of antibiotics within 2 weeks prior to Screening.
• . Supine resting blood pressure (BP) \>140/90 mmHg or heart rate (HR) \>100 beats per minute at Screening and at Day -2.
• . Clinically significant abnormality on ECG performed at the Screening Visit or prior to administration of the initial dose of study drug. (Abnormalities include not being in sinus rhythm, IVCD/BBB or QTcF\>450 ms for males (470 ms for females)).
• . Out of range (on repeat) testing for coagulation tests.